SODIUM PHOSPHATE P 32
LOE Approachingsodium phosphate p-32
NDAINJECTION, ORALSOLUTION
Approved
Mar 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SODIUM PHOSPHATE P 32 (sodium phosphate p-32) is clinical pharmacology vecuronium is a nondepolarizing neuromuscular blocking agent possessing all of the characteristic pharmacological actions of this class of drugs (curariform). First approved in 1959.
Drug data last refreshed 22h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sodium Phosphate P-32 is a radioactive phosphate compound used as a diagnostic and therapeutic agent in nuclear medicine. The product acts as a phosphate analog that localizes to areas of high metabolic activity, particularly in bone and soft tissue lesions. It is administered intravenously for imaging and treatment of select malignancies and hematologic disorders.
LOE Approaching
Product approaching loss of exclusivity with minimal linked job opportunities; legacy radiopharmaceutical with limited commercial growth trajectory.
Mechanism of Action
CLINICAL PHARMACOLOGY Vecuronium is a nondepolarizing neuromuscular blocking agent possessing all of the characteristic pharmacological actions of this class of drugs (curariform). It acts by competing for cholinergic receptors at the motor end-plate. The antagonism to acetylcholine is inhibited…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.